<a href="https://www.fiercebiotech.com/biotech/parabilis-preps-413m-ipo-fuel-desmoid-tumor-drug-phase-3" hreflang="en">Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3</a>
Parabilis Medicines is preparing for an IPO that could raise up to $476 million to fund the phase 3 development of its drug for desmoid tumors, with plans to offer 25 million shares priced between $17 and $19. The company aims to advance its Wnt/β-catenin pathway inhibitor, zolucatetide, and other assets while also receiving substantial investments from Regeneron.
Parabilis Medicines is preparing for a significant IPO, potentially raising up to $476 million to fund phase 3 development of its desmoid tumor drug, zolucatetide, which has already received FDA fast-track designation. This move underscores a strategic focus on advancing precision therapies for rare conditions and could be a key opportunity for investors interested in biotech IPOs, especially given Parabilis' innovative approach with helicon peptides and substantial backing from previous financing rounds.